
    
      A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study
      to Assess the Pharmacokinetics, Safety and Tolerability of Two Different Extended Release
      Formulations of Tablets of AZD3241 (300 mg) after Administration of Multiple Doses in Healthy
      Male and Female Volunteers
    
  